Meeting News

Meeting News

On location

Pinpointing the Mechanisms that Transform MGUS into Myeloma

A molecular study of monoclonal gammopathy of undetermined significance (MGUS) and myeloma has provided new insight into the biology of myeloma, finding that MGUS...
On location

IMWG Revises International Staging System for Multiple Myeloma

At this year’s International Myeloma Working Group (IMWG) Summit, this large team of myeloma experts released a revised International Staging System (R-ISS) for newly...
On location

Adding Elotuzumab to Standard Therapy Reduces Progression Risk for Multiple Myeloma Patients

Elotuzumab, a novel anti-SLAMF7 monoclonal antibody, extended multiple myeloma (MM) patients’ duration of remission by about five months, on average, compared with standard treatment...

Safety Profile of Daratumumab in Relapsed/Refractory Multiple Myeloma Patients

For relapsed/refractory multiple myeloma (MM) patients treated with the anti-CD38 monoclonal antibody daratumumab, as with other monoclonal antibody therapies, management of infusion-related reactions (IRRs)...
On location

Safety and Tolerability of MOR202 in Relapsed/Refractory Myeloma Patients

A recent phase I/IIa study evaluated the safety and efficacy of MOR202, a human monoclonal anti-CD38 antibody, in adult patients with relapsed/refractory multiple myeloma...

Researchers Identify Markers of Relapse in Post-Transplant Multiple Myeloma Patients

Results from an analysis presented at the 2015 ASH Meeting on Hematologic Malignancies confirm that T-cell exhaustion and senescence (occurring when T cells are...
Advertisement

Current Issue

September 2019 Volume 5 Issue 11

September 2019, Volume 5, Issue 11

This issue explores politics in the exam room, demystifies proteomic analysis in hematology, and more.